Symbiotic Capital

Symbiotic Capital provides specialized credit solutions tailored for the life sciences sector, acting as a non-bank lender. The firm offers healthcare credit, specifically designed by and for those deeply embedded in scientific innovation. Its core approach leverages deep industry expertise to support companies requiring flexible financing structures beyond traditional venture capital or debt options.

The firm launched recently, co-founded by biotech magnate Dr. Arie Belldegrun, former Roche CEO Franz Humer, and Himani Bhalla, who serves as Chief Investment Officer. Their collective insight stemmed from recognizing a critical need within the life sciences ecosystem for financing partners who truly understand the unique challenges and opportunities in bringing scientific breakthroughs to market, combining extensive experience in drug development, corporate leadership, and financial structuring.

Symbiotic Capital primarily serves life science companies, offering them bespoke credit facilities that align with the often-long development cycles and regulatory pathways of the industry. The company’s vision is to accelerate the development of groundbreaking scientific advancements by providing capital that is both strategic and patient, empowering innovators to focus on their research and development without being constrained by conventional funding models.